Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor

Journal of Medicinal Chemistry
Yujun ZhaoShaomeng Wang

Abstract

We report the structure-based discovery of CF53 (28) as a highly potent and orally active inhibitor of bromodomain and extra-terminal (BET) proteins. By the incorporation of a NH-pyrazole group into the 9H-pyrimido[4,5- b]indole core, we identified a series of compounds that bind to BRD4 BD1 protein with Ki values of <1 nM and achieve low nanomolar potencies in the cell growth inhibition of leukemia and breast cancer cells. The most-promising compound, CF53, possesses excellent oral pharmacokinetic properties and achieves significant antitumor activity in both triple-negative breast cancer and acute leukemia xenograft models in mice. Determination of the co-crystal structure of CF53 with the BRD4 BD1 protein provides a structural basis for its high binding affinity to BET proteins. CF53 is very selective over non-BET bromodomain-containing proteins. These data establish CF53 as a potent, selective, and orally active BET inhibitor, which warrants further evaluation for advanced preclinical development.

References

Aug 7, 2001·Frontiers in Bioscience : a Journal and Virtual Library·B Florence, D V Faller
Jul 4, 2003·Proceedings of the National Academy of Sciences of the United States of America·Anup DeyKeiko Ozato
Jul 16, 2003·Molecular and Cellular Biology·Christophe Pivot-PajotSaadi Khochbin
Aug 1, 2007·Journal of Applied Crystallography·Airlie J McCoyRandy J Read
Jan 9, 2010·Acta Crystallographica. Section D, Biological Crystallography·Vincent B ChenDavid C Richardson
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Jun 23, 2012·Nature Reviews. Cancer·Anna C Belkina, Gerald V Denis
Nov 20, 2013·Proceedings of the National Academy of Sciences of the United States of America·Sarah PicaudPanagis Filippakopoulos
Apr 23, 2014·Nature Reviews. Drug Discovery·Panagis Filippakopoulos, Stefan Knapp
Jan 9, 2015·Acta Crystallographica. Section C, Structural Chemistry·George M Sheldrick
Sep 20, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Stephen J NichollsSteven E Nissen
Nov 26, 2015·ACS Chemical Biology·Steven G Smith, Ming-Ming Zhou
Jun 14, 2016·Current Opinion in Chemical Biology·Natalie H TheodoulouPhilip G Humphreys
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor
Feb 15, 2017·Journal of Medicinal Chemistry·Zhiqing LiuJia Zhou

❮ Previous
Next ❯

Citations

Nov 14, 2018·Molecular Diversity·Alejandro Speck-Planche, Marcus T Scotti
Apr 30, 2021·Angewandte Chemie·Guangyan DuNathanael S Gray
Sep 10, 2020·Current Topics in Medicinal Chemistry·Feng SongMeng Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.